Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions

Executive Summary

Novartis' discussions with FDA regarding use of the trade name Zelmac for the irritable bowel syndrome therapy (tegaserod) may lead to the company launching the product under a different name.

You may also be interested in...



Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force

Novartis plans to launch a national DTC campaign for its irritable bowel syndrome agent Zelnorm early in the third quarter, the company announced during its July 21 investor conference call

Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force

Novartis plans to launch a national DTC campaign for its irritable bowel syndrome agent Zelnorm early in the third quarter, the company announced during its July 21 investor conference call

Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months

The uptake of Novartis' irritable bowel syndrome therapy Zelnorm will accelerate after physicians obtain more "feedback" from early users, U.S. Commercial Operations General Manager Kurt Graves said Oct. 17 during a Novartis R&D briefing in New York City

Related Content

UsernamePublicRestriction

Register

PS037367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel